

Table S5 Baseline and Week 16 and 52 concomitant NSAID use and ASAS-NSAID scores: COAST-V and COAST-W
(ETP population: observed data)

	COAST-V (bDMARD-naïve)				COAST-W (TNFi-experienced)		
	PBO/ IXE (N=86)	ADA/ IXE (N=86)	IXE Q4W/ IXE Q4W (N=78)	IXE Q2W/ IXE Q2W (N=79)	PBO/ IXE (N=93)	IXE Q4W/ IXE Q4W (N=98)	IXE Q2W/ IXE Q2W (N=90)
Concomitant NSAID use, n (%)							
Baseline	78/86 (90.7)	80/86 (93.0)	71/78 (91.0)	76/79 (96.2)	75/93 (80.6)	75/98 (76.5)	64/90 (71.1)
Week 16	79/86 (91.9)	80/86 (93.0)	70/78 (89.7)	76/79 (96.2)	74/93 (79.6)	74/98 (75.5)	62/90 (68.9)
Week 52	72/83 (86.7)	72/82 (87.8)	59/73 (80.8)	66/74 (89.2)	62/81 (76.5)	71/89 (79.8)	55/80 (68.8)
ASAS-NSAID*, mean (SD)							
Baseline	83.3 (26.6)	81.8 (27.1)	75.6 (29.2)	84.9 (29.7)	82.2 (36.3)	80.4 (40.4)	91.0 (37.5)
Change from baseline							
Week 16	-0.9 (7.9)	0.5 (4.6)	-2.1 (12.7)	0.3 (4.2)	-0.7 (11.4)	-1.5 (9.6)	-4.7 (17.8)
Week 52	-10.3 (27.5)	-5.9 (20.9)	-7.6 (25.4)	-9.9 (27.9)	-9.8 (34.4)	-5.5 (19.6)	-2.3 (24.0)

*Among patients who were receiving concomitant NSAIDs at baseline. COAST-V: N=78 (PBO/IXE), N=80 (ADA/IXE), N=71 (IXE Q4W/IXE Q4W), and N=76 (IXE Q2W/IXE Q2W); COAST-W: N=75 (PBO/IXE), N=75 (IXE Q4W/IXE Q4W), and N=64 (IXE Q2W/IXE Q2W).

ADA, adalimumab; ASAS, Assessment of SpondyloArthritis international Society; bDMARD, biological disease-modifying antirheumatic drug; ETP, extended treatment period; IXE Q4W, ixekizumab 80 mg every 4 weeks; IXE Q2W, ixekizumab 80 mg every 2 weeks; NSAID, nonsteroidal anti-inflammatory drug; PBO, placebo; SD, standard deviation; TNFi, tumour necrosis factor inhibitor.